Abstract:Background: Since 2019, the SARS-CoV-2 virus has been responsible for the global spread of respiratory illness. As of 1 September 2024, the cumulative number of infections worldwide exceeded 776 million. There are many structural proteins of the virus, among which the SARS-CoV-2 nucleocapsid (N) protein plays a pivotal role in the viral life cycle, participating in a multitude of essential activities following viral invasion. An important antiviral immune response is the major histocompatibility complex (MHC)-restricted differentiation cluster 8 (CD8+) T cell cytotoxicity. Therefore, understanding the immunogenicity of SARS-CoV-2 NP-specific MHC-I-restricted epitopes is highly important. Methods: MHC-I molecules from 11 human leukocyte antigen I (HLA-I) superfamilies with 98% population coverage and 6 mouse H2 alleles were selected. The affinity were screened by IEDB, NetMHCpan, SYFPEITHI, SMMPMBEC and Rankpep. Further immunogenicity and conservative analyses were performed using VaxiJen and BLASTp, respectively. EpiDock was used to simulate molecular docking. Cluster analysis was performed. Selective epitopes were validated by enzyme-linked immunospot (ELISpot) assay and flow cytometry in the mice with pVAX-NPSARS-CoV-2 immunization. Enzyme-Linked Immunosorbent Assay (ELISA) was used to detect whether the preferred epitope induced humoral immunity. Results: There were 64 dominant epitopes for the H-2 haplotype and 238 dominant epitopes for the HLA-I haplotype. Further analysis of immunogenicity and conservation yielded 8 preferred epitopes, and docking simulations were conducted with corresponding MHC-I alleles. The relationships between the NP peptides and MHC-I haplotypes were then determined via two-way hierarchical clustering. ELISA, ELISpot assay, and flow cytometry revealed that the preferred epitope stimulated both humoral and cellular immunity and enhanced cytokine secretion in mice. Conclusions: our study revealed the general patterns among multiple haplotypes within the humans and mice superfamily, providing a comprehensive assessment of the pan-MHC-I immunoreactivity of SARS-CoV-2 NP. Our findings would render prospects for the development and application of epitope-based immunotherapy in lasting viral epidemics.

The immunodominant and neutralization linear epitopes for SARS-CoV-2

Mapping the Immunodominance Landscape of SARS-CoV-2 Spike Protein for the Design of Vaccines Against COVID-19

A key linear epitope for a potent neutralizing antibody to SARS-CoV-2 S-RBD

Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2

A key linear epitope for a potent neutralizing antibody to SARS CoV 2 S RBD

Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2

Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients

T and B cell Epitope analysis of SARS‐CoV‐2 S protein based on immunoinformatics and experimental research

Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen

Epitope-based peptide vaccine design and target site characterization against novel coronavirus disease caused by SARS-CoV-2

Bioinformatics-based SARS-CoV-2 epitopes design and the impact of spike protein mutants on epitope humoral immunities.

Identification of Three Conserved Linear B Cell Epitopes on the SARS-CoV-2 Spike Protein

Identification of Four Linear B-cell Epitopes on the SARS-CoV-2 Spike Protein Able to Elicit Neutralizing Antibodiesidentification of Four Linear B-cell Epitopes on the SARS-CoV-2 Spike Protein Able to Elicit Neutralizing Antibodies

T cell epitope mapping reveals immunodominance of evolutionarily conserved regions within SARS-CoV-2 proteome.

Immunoreactivity Analysis of MHC-I Epitopes Derived from the Nucleocapsid Protein of SARS-CoV-2 via Computation and Vaccination

Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2

Identification and Characterization of Novel Neutralizing Epitopes in the Receptor-Binding Domain of SARS-CoV Spike Protein: Revealing the Critical Antigenic Determinants in Inactivated SARS-CoV Vaccine.

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes

Identification of Closed Linear Epitopes in S1-RBD and S2-HR1/2 of SARS-CoV-2 Spike Protein Able to Induce Neutralizing Abs

Design of the conserved epitope peptide of SARS-CoV-2 spike protein as the broad-spectrum COVID-19 vaccine

Multi-epitopevaccine design using an immunoinformaticsapproach for 2019 novelcoronavirus in China (SARS-CoV-2)